CIAN
BIO icon

Capstone Investment Advisors (Netherlands)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capstone Investment Advisors (Netherlands)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,449
Closed -$289K – 132
2017
Q1 		$289K Sell
1,449
-325
-18% -$62.6K 0.82% 42
2016
Q4 		$323K Buy
+1,774
New +$302K 0.55% 32

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capstone Investment Advisors (Netherlands)'s BIO Position: Q2 2017 in Review

Capstone Investment Advisors (Netherlands) sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2017, closing a stake of 1,449 shares — an estimated $289K sold.

Capstone Investment Advisors (Netherlands) first reported a position in BIO in Q4 2016 and held it in 2 quarters. The position peaked at $323K in Q4 2016. 276 funds tracked by Wall St. Rank hold BIO as of Q2 2017.

  • Capstone Investment Advisors (Netherlands) reported no remaining Bio-Rad Laboratories Class A position as of Q2 2017 after selling out during the quarter.
  • Capstone Investment Advisors (Netherlands) sold 1,449 Bio-Rad Laboratories Class A shares in Q2 2017, an estimated $289K.
  • Capstone Investment Advisors (Netherlands) first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and held it in 2 quarters.
  • Capstone Investment Advisors (Netherlands)'s Bio-Rad Laboratories Class A position peaked at $323K in Q4 2016.
  • 276 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2017.

Based on Capstone Investment Advisors (Netherlands)'s 13F filing for Q2 2017, filed 14 Aug 2017.